Sports Talk

Inaugural panel discussion dives deep into emerging tech partnerships

Courtesy photo

On March 24, more than 100 guests gathered at alliantgroup's head-turning conference center in the Galleria area for an exciting discussion on the sportstech industry, co-sponsored by InnovationMap. The panelists included Houston-based thought leaders, founders, and investors who shared their insights while discussing how the city of Houston can emerge as a leader in sports technology.

With the backdrop of Houston’s skyline, the event began with an hour of networking, drinks, and light bites. Then alliantgroup’s CEO, Dhaval Jadav, kicked off the discussion by sharing his enthusiasm for the inaugural Future Focus series and introduced David Gow as the moderator for the night’s topic.

Gow is the CEO of Gow Media and the CEO of a SPAC (Special Purpose Acquisition Corp) that has raised $115 million to invest in sportstech. He explained how “technology is transforming the sports industry, creating new billion-dollar industries seemingly overnight.”

He defined sportstech within four categories: health and performance, fan engagement, e-sports, and fantasy and gambling. Across these categories, technology is enabling interconnectedness through social interaction, new communities, improved health, subscriber-based business models, software as a service, and new revenue streams.

And this doesn’t even do justice to all the changes happening with NIL, NFTs and Web3.

The panel included an all-star cast, with two from academia, an executive from the Houston Astros, and two sportstech entrepreneurs:

  • Beena George, chief innovation officer and professor of management at University of St. Thomas
  • Tom Stallings, professor of sports management at Rice University
  • Jimmy Comerota, director of strategic partnerships for the Houston Astros
  • Dez, co-creator of Apollo Houston
  • Jorge Ortiz, CEO of VarsityHype

Future Focus sportstech

Courtesy photo

Gow began by asking the panelists “which innovation intrigues you the most?” and responses ranged from wearables to enhance wellness to new training equipment to the rise of e-sports and the metaverse, the latter of which Ortiz displayed particular enthusiasm about. He has already made a bet on the future — last year he bought a tavern in the metaverse, naming it “Isla,” after his newborn.

Gow cited Houston-based company nVenue as being well positioned for the future of sports betting.

“The company will profit from microbetting, which is rapid bets on individual moments within a game, e.g. a bet on whether a batter will get on base, etc," said Gow. "It takes raw, historical data, such as a batting average, and turns it into betting odds real-time, pitch by pitch.”

George noted that University of St. Thomas now has an e-sports team. “The young demo in e-sports suggests a high-growth future,” she shared.

The panel agreed that we are already seeing the impacts on the merging of sports and technology and how it’s shaping our engagement here in Houston.

"Everyone that knows me knows that I am a sports fanatic, and I was absolutely blown away by the panel and their discussion on what’s on the horizon for the fan experience," said Jadav. "I was riveted by the discussion and they covered so many exciting topics. I am also super excited about how Web3 and the metaverse will change how we interact with athletes and creatives and create a more immersive experience for all. I can’t wait for the next event.”

Future Focus: Sportstech was the first of many planned discussions that alliantgroup and InnovationMap are hosting. The series was created as a way for industry leaders and burgeoning startups to exchange ideas and talk about what the future of technology looks like for all of us.

The next event will focus on spacetech and is scheduled for May 5. It will be moderated by alliantgroup chairman of robotics and artificial intelligence Dr. Robert Ambrose, who recently retired from NASA, where he served as the chief of software, robotics, and simulation division at NASA’s Johnson Space Center in Houston.

The panel will include Dr. Seth Shotak, senior astronomer and director of the Center for SETI Research at the SETI Institute in California.

These Future Focus panels are free to attend, though registration is encouraged.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted